STUDY ON SERUM LEVELS OF HBV DNA, HBsAg, AND HBeAg IN PATIENTS WITH CHRONIC HEPATITIS B AND CIRRHOSIS IN CAN THO CENTRAL GENERAL HOSPITAL IN 2024–2025

Background: Chronic hepatitis B with cirrhosis is a severe condition that has a high risk of complications such as liver failure, hepatocellular carcinoma and death. Monitoring biomarkers such as HBV-DNA, HBsAg, and HBeAg plays a crucial role in assessing viral activity, predicting disease progression, and guiding effective treatments. Objectives: To determine HBV-DNA, HBsAg, and HBeAg levels and learn about some factors associated with these markers in patients with chronic hepatitis B with cirrhosis at Can Tho Central General Hospital during 2024–2025. Materials and methods: A cross-sectional analytical study was conducted on 120 patients who were diagnosed with chronic hepatitis B and cirrhosis andwere examined and treated in Can Tho Central General from June 2024 to February 2025. Patients underwent testing for AST, ALT, bilirubin, albumin, HBV-DNA viral load, HBsAg, and HBeAg. Data were collected and analyzed using SPSS 26.0. Results: The average concentration of the tests with AST is 161.42 ± 236.46 U/L, ALT: 162.05 ± 318.43 U/L, bilirubin: 59.79 ± 109.18 µmol/L, albumin: 29.15 ± 6.43 g/L, HBV-DNA viral load: 5.88 ± 2.37 log10 copies/mL, HBsAg: 3.30 ± 0.46 log10 IU/mL, and the HBeAg (+) rate is 17.5%. Conclusion: The study shows an association between elevated AST, ALT, and bilirubin levels and decreased albumin levels with HBV-DNA concentration (p<0.05), but no relation with HBeAg (p>0.05). Additionally, a relationship is found between AST and albumin with HBsAg levels (p<0.05). Notably, HBV-DNA and HBsAg are closely related (p = 0.001), and the proportion of HBeAg-positive cases is also associated with HBV-DNA levels (p = 0.007). However, there is no statistically significant difference in HBsAg levels between the HBeAg-positive and HBeAg-negative groups (p = 0.974).